These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20629598)

  • 1. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
    Ge J; Zhu J; Hong BK; Boonbaichaiyapruck S; Goh YS; Hou CJ; Pinton P
    Curr Med Res Opin; 2010 Sep; 26(9):2077-85. PubMed ID: 20629598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of prasugrel for the secondary prevention of atherothrombosis.
    Spinler SA; Rees C
    J Manag Care Pharm; 2009 Jun; 15(5):383-95. PubMed ID: 19496635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
    Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
    Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
    Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
    J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
    Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
    Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
    Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Norgard NB; Abu-Fadel M
    Vasc Health Risk Manag; 2009; 5():873-82. PubMed ID: 19898643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical review of prasugrel for formulary decision makers.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
    Jakubowski JA; Matsushima N; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Br J Clin Pharmacol; 2007 Apr; 63(4):421-30. PubMed ID: 17076696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
    Saito S; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Nakamura M
    Circ J; 2014; 78(7):1684-92. PubMed ID: 24759796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
    Lee DH; Kim MH; Park TH; Park JS; Park K; Zhang HZ; Seo JM; Lee MS
    Trials; 2013 Feb; 14():62. PubMed ID: 23448344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
    Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.